Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893799 · ClinicalTrials.gov registry record · Phase 1
A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease
A Phase 1 study, sponsored by Renibus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03893799 is a Phase 1 study that has completed, run by Renibus Therapeutics. The registered enrollment target is 54 participants.
The verdict
NCT03893799, a Phase 1 study, has completed, sponsored by Renibus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with Stage 3/4 CKD.
Interventions
- DRUG RBT-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03893799
The ClinicalTrials.gov registry entry for NCT03893799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renibus Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RBT-1 is the first listed.
NCT03893799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03893799 about?
NCT03893799 is a clinical study titled "A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease". This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with Stage 3/4 CKD.
What is the current status of trial NCT03893799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-08-27. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03893799?
The interventions under investigation include: RBT-1 (DRUG).
Who is sponsoring clinical trial NCT03893799?
This trial is sponsored by Renibus Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.